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Background: Vitamin K antagonists have been the only available option for oral anticoagulation for several decades. The recently published RE-
LY trial established dabigatran as an equally effective and safe alternative to warfarin. One year after the FDA approval of dabigatran, we sought to 
determine the safety, efficacy, and tolerability of dabigatran in a community setting.
Methods: We retrospectively analyzed the demographics, bleeding rates, stroke rates, and any reasons for discontinuation of dabigatran in patients 
who were treated with dabigatran for non-valvular atrial fibrillation over the 12 month period between November 2010 (FDA approval of dabigran) 
through October 2011.
Results: A total of 136 patients were included in the retrospective analysis. The mean age of patients was 74.8 years (range 38 to 92) and 41.2% 
were female. The dose of dabigatran was 150 mg BID in 98.1% of patients and 75 mg BID in 1.9%. Of the 136 patients, 44 stopped the drug: 
three secondary to major life-threatening bleed, ten secondary to minor gastrointestinal bleed, two secondary to hematuria , one secondary to 
hemoptysis, and 28 secondary to side effects, most frequently gastrointestinal. Bleeding was noted more frequently in patients over 75 of age. There 
was no difference in bleeding between men and women. No patients were noted to have strokes or intracranial bleed while on dabigatran. The most 
common reason cited by patients who were offered dabigatran but did not opt to start the medication was concern about potential side effects. The 
use of dabigatran was also prohibited by cost and lack of insurance coverage.
Conclusions: Dabigatran is an attractive alternative to warfarin as there is no need for routine INR testing, a lack of drug-drug and food-drug 
interactions, and it is easy to administer. In this retrospective analysis, a significant proportion of patients started on dabigatran discontinued it 
secondary to intolerable side effects and minor bleeding. Given that the medication has been in use for less than a year, long term follow up data for 
efficacy and safety are lacking.
